- Home
- LTBR vs KROS Comparison
LTBR vs KROS Comparison
Compare LTBR & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTBR
- KROS
- Stock Information
- Founded
- LTBR 1992
- KROS 2015
- Country
- LTBR United States
- KROS United States
- Employees
- LTBR N/A
- KROS N/A
- Industry
- LTBR Professional Services
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- LTBR Consumer Discretionary
- KROS Health Care
- Exchange
- LTBR Nasdaq
- KROS Nasdaq
- Market Cap
- LTBR 578.2M
- KROS 565.0M
- IPO Year
- LTBR N/A
- KROS 2020
- Fundamental
- Price
- LTBR $17.77
- KROS $17.36
- Analyst Decision
- LTBR
- KROS Buy
- Analyst Count
- LTBR 0
- KROS 15
- Target Price
- LTBR N/A
- KROS $22.10
- AVG Volume (30 Days)
- LTBR 1.7M
- KROS 1.2M
- Earning Date
- LTBR 11-05-2025
- KROS 11-05-2025
- Dividend Yield
- LTBR N/A
- KROS N/A
- EPS Growth
- LTBR N/A
- KROS N/A
- EPS
- LTBR N/A
- KROS 1.57
- Revenue
- LTBR N/A
- KROS $246,718,000.00
- Revenue This Year
- LTBR N/A
- KROS $6,657.47
- Revenue Next Year
- LTBR N/A
- KROS N/A
- P/E Ratio
- LTBR N/A
- KROS $10.96
- Revenue Growth
- LTBR N/A
- KROS 37798.31
- 52 Week Low
- LTBR $4.37
- KROS $9.12
- 52 Week High
- LTBR $31.34
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- LTBR 39.41
- KROS 68.38
- Support Level
- LTBR $19.00
- KROS $16.30
- Resistance Level
- LTBR $20.85
- KROS $17.30
- Average True Range (ATR)
- LTBR 2.48
- KROS 0.60
- MACD
- LTBR -0.86
- KROS 0.23
- Stochastic Oscillator
- LTBR 9.19
- KROS 87.59
About LTBR Lightbridge Corporation
Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, which is the development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.